FTC requiring Aurobindo Pharma to divest from four drug products to complete acquistion of Lannett

The U.S. FTC is conditioning Aurobindo Pharma's $250 million acquisition of Lannett on the divestiture of four generic drug products. The remedy reduces transaction freedom and may trim the strategic value of the deal, though it does not block closing. The impact is likely specific to the companies involved rather than broad sector-wide.

Analysis

The U.S. FTC is conditioning Aurobindo Pharma's $250 million acquisition of Lannett on the divestiture of four generic drug products. The remedy reduces transaction freedom and may trim the strategic value of the deal, though it does not block closing. The impact is likely specific to the companies involved rather than broad sector-wide.